We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

47 hedge funds and large institutions have $122M invested in Orchard Therapeutics plc American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more capital invested

Capital invested by funds: $46.9M → $122M (+$75.1M)

145% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 11

47% more funds holding

Funds holding: 32 → 47 (+15)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

99% less call options, than puts

Call options by funds: $26K | Put options by funds: $2.07M

Holders
47
Holders Change
+15
Holders Change %
+46.88%
% of All Funds
0.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
27
Increased
5
Reduced
4
Closed
11
Calls
$26K
Puts
$2.07M
Net Calls
-$2.04M
Net Calls Change
-$2.18M

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$25.2M
2
BCM
Beryl Capital Management
California
+$24.6M
3
LP
LMR Partners
United Kingdom
+$5.23M
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
+$4.72M
5
Millennium Management
Millennium Management
New York
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.44M
2
PIM
Platinum Investment Management
Australia
-$1.92M
3
Mariner
Mariner
Kansas
-$1.49M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$936K
5
Citadel Advisors
Citadel Advisors
Florida
-$739K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$406K +$390K +24,737 New
GI
27
GAMCO Investors
Connecticut
$250K +$239K +15,188 New
GS
28
GTS Securities
New York
$247K +$236K +15,000 New
FIA
29
FNY Investment Advisers
New York
$246K +$236K +15,000 New
VA
30
Vident Advisory
Georgia
$185K +$177K +11,270 New
WP
31
Woodline Partners
California
$165K – – –
HM
32
Harvest Management
New York
$165K +$157K +10,000 New
Morgan Stanley
33
Morgan Stanley
New York
$71.9K -$120K -7,616 -64%
EC
34
EntryPoint Capital
New York
$33.2K +$31.8K +2,020 New
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$21.7K +$18.5K +1,176 +828%
Group One Trading
36
Group One Trading
Illinois
$19.7K +$18.8K +1,197 New
Wells Fargo
37
Wells Fargo
California
$18.9K -$1.57K -100 -8%
Osaic Holdings
38
Osaic Holdings
Arizona
$9.24K -$12.4K -790 -58%
BCV
39
Banque Cantonale Vaudoise
Switzerland
$7K -$157K -10,000 -96%
UBS Group
40
UBS Group
Switzerland
$6.25K – – –
Bank of America
41
Bank of America
North Carolina
$4.66K – – –
Citigroup
42
Citigroup
New York
$1.81K – – –
CWP
43
Concord Wealth Partners
Virginia
$1.65K – – –
Carson Wealth (CWM LLC)
44
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
BHWM
45
Beaird Harris Wealth Management
Texas
$198 – – –
MAWCM
46
Mine & Arao Wealth Creation & Management
California
$165 – – –
CWM
47
Compass Wealth Management
Connecticut
$149 +$142 +9 New
DM
48
Deerfield Management
New York
– -$2.44M -316,169 Closed
PIM
49
Platinum Investment Management
Australia
– -$1.92M -248,462 Closed
Mariner
50
Mariner
Kansas
– -$1.49M -192,250 Closed
1
2
3

ORTX Hedge Fund Activity: Q4 2023 in Review

47 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2023, worth a combined $122M — up 160% from $46.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ORTX positions and 11 closed out — a net gain of 16 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $25.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.44M sold.

  • 47 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2023, up from 32 in Q3 2023.
  • Funds reported $122M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2023, up 160% quarter-over-quarter.
  • 27 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2023 and 11 closed out, a net change of +16 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $25.2M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2023 was Deerfield Management, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2023.